时间:2023-12-04 21:30:26 来源:网络整理 编辑:자동차
Celltrion Healthcare, South Korean biosimilar giant Celltrion’s sales unit, announced Wednesday that
Celltrion Healthcare, South Korean biosimilar giant Celltrion’s sales unit, announced Wednesday that the company has won the United Nations Development Program’s tender to supply anticancer drugs to Turkmenistan.
The UNDP is a UN agency dedicated to eradicating poverty and reducing inequalities through the sustainable development of nations in more than 170 countries and territories.
Celltrion Healthcare said the company joined the tender that opened in May this year, and that the result was announced last month.
According to Celltrion Healthcare, the company will supply its blood cancer biosimilar Truxima, and its metastatic colorectal and breast cancer treatment Vegzelma to Turkmenistan.
The company added that the supply of anticancer biosimilars is expected to begin by the end of this year.
The value of the tender, as well as the quantity of its anticancer treatments supply, have not been disclosed by the company.
“It is meaningful for us to supply our treatments to help patients in the country,” an official from Celltrion Healthcare said. “We believe that Truxima and Vegzelma will become the most effective, and economically viable treatment options, not only in developed countries but also in developing countries."
Celltrion Healthcare said that the company will participate more in international organizations’ tenders in the future.
Both Truxima and Vegzelma are widely prescribed anticancer treatments developed by Celltrion.
According to the world’s largest contract research organization IQVIA’s data, Truxima, the first biosimilar of Roche’s blockbuster cancer drug Rituxan, has secured 22 percent market share in the European market as of the second quarter this year. In the US, its market share stood at 30 percent in the third quarter, according to separate data from Symphony Health.
Vegzelma, an anti-cancer monoclonal antibody treatment biosimilar to Avastin, is increasing its presence in European countries after its launch in October 2022, Celltrion Healthcare said. The drug's market shares in Finland and Germany stood at 45 percent and 21 percent, respectively.
[Global Finance Awards] Going global essential in era of digital finance2023-12-04 21:15
Cheongju Craft Biennale stresses connection with nature, Jikji legacy2023-12-04 21:09
Jungkook of BTS to hold fan showcase on Nov. 202023-12-04 20:54
For esports fans, more activities await beyond LoL matches2023-12-04 20:32
[New in Korean] 'BU Care Insurance' protects hearts after breakups2023-12-04 20:27
Uncertainties remain for Samsung, SK after US eases export controls2023-12-04 20:18
[Photo News] Housing solutions in Asia2023-12-04 20:12
尹대통령 지지율, 1.1%p 내린 38.9% [알앤써치]2023-12-04 20:01
Spicing up the world: Samyang’s Buldak series makes global waves2023-12-04 19:13
Performing Arts Market to link local artists to world2023-12-04 18:49
[New in Korean] 'BU Care Insurance' protects hearts after breakups2023-12-04 21:03
Seoul shares open higher on US gains; Israel2023-12-04 20:29
Seoul shares open higher on US gains; Israel2023-12-04 20:29
US eases export controls on chip equipment for Samsung, SK factories in China2023-12-04 20:21
Ilyon Woo's nonfiction lands on NYT's 10 best books of 20232023-12-04 20:06
[Today’s K2023-12-04 19:48
Seoul shares close tad higher ahead of key US jobs data2023-12-04 19:38
[From the scene] Eye2023-12-04 19:36
Former head of Jogye Order dies in temple fire2023-12-04 19:26
김건희 여사, 광주디자인비엔날레 찾아 “문화예술계 육성 의지”2023-12-04 19:23